Rapid response of spesolimab in biologics - failure patient with generalized pustular psoriasis flare.

IF 1.4 4区 医学 Q3 ALLERGY
Meng Jiang, Yan Li, Xin Guan, Linfeng Li, Wei Xu
{"title":"Rapid response of spesolimab in biologics - failure patient with generalized pustular psoriasis flare.","authors":"Meng Jiang, Yan Li, Xin Guan, Linfeng Li, Wei Xu","doi":"10.5114/ada.2023.129514","DOIUrl":null,"url":null,"abstract":"Generalized pustular psoriasis (GPP) is an intractable autoinflammatory skin disease characterized by diffused erythematous rashes and recurrent flares of pustular [1]. Effisayil™ 1 trial showed the IL-36 antibody spesolimab could bring fast clearance of pustules and lesions and excellent patient safety profile, which made it the first treatment option in the GPP flare approved by the Unit - ed States (US) [2, 3]. However, the efficacy and safety of spesolimab in Chinese population has not been clearly reported. We herein reported a Chinese case with a GPP flare who is heavily treated with other biologics but with poor response, and was successfully treated with spe - solimab. A 34-year-old female patient visited our department due to a 2-year history of GPP with a poor treatment ef - fect. She had a history of recurrent plaque-type psoriasis","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/e1/PDIA-40-51107.PMC10485750.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2023.129514","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Generalized pustular psoriasis (GPP) is an intractable autoinflammatory skin disease characterized by diffused erythematous rashes and recurrent flares of pustular [1]. Effisayil™ 1 trial showed the IL-36 antibody spesolimab could bring fast clearance of pustules and lesions and excellent patient safety profile, which made it the first treatment option in the GPP flare approved by the Unit - ed States (US) [2, 3]. However, the efficacy and safety of spesolimab in Chinese population has not been clearly reported. We herein reported a Chinese case with a GPP flare who is heavily treated with other biologics but with poor response, and was successfully treated with spe - solimab. A 34-year-old female patient visited our department due to a 2-year history of GPP with a poor treatment ef - fect. She had a history of recurrent plaque-type psoriasis

Abstract Image

spesolimab在生物制剂中的快速反应-广泛性脓疱性银屑病发作失败患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信